Email this article 
Resolution of the Expert Council “Current approaches to pharmacotherapy of non-metastatic castration-resistant prostate cancer”
- Authors: Editorial a.
- Issue: Vol 16, No 4 (2020)
- Pages: 220-223
- Section: RESOLUTION
- Published: 30.12.2020
- URL: https://oncourology.abvpress.ru/oncur/article/view/1420
- DOI: https://doi.org/10.17650/1726-9776-2020-16-4-220-223
- ID: 1420
Cite item
Full Text
Abstract
.
References
- Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
- State of oncological care in Russia in 2018. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsen a – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 236 p. (In Russ.).
- Alekseev B.Ya. New treatment standard for patients with non-metastatic castration-resistant prostate cancer. Onkourologiya = Cancer Urology 2018;14(3):68–77. (In Russ.). doi: 10.17650/1726-9776-2018-14-3-68-77.
- Smith M.R., Saad F., Oudard S. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate- specific antigen doubling time. J Clin Oncol 2013;31(30):3800–6. doi: 10.1200/JCO.2012.44.6716.
- Clinical guidelines. Prostate cancer. Association of Oncologists of Russia, 2019. (In Russ.).
- Shore N., Zurth C., Fricke R. et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration- resistant prostate cancer: results of pre- specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol 2019;14(5):527–39. doi: 10.1007/s11523-019-00674-0.
- Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–46. doi: 10.1056/NEJMoa1815671.
- Fizazi K., Shore N., Tammela T.L. et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383(11):1040–9. doi: 10.1056/NEJMoa2001342.
Supplementary files
